Matija Tomsic Selected Research

dopastin

10/2009

Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matija Tomsic Research Topics

Disease

11	Rheumatoid Arthritis 01/2020 - 09/2008
4	Axial Spondyloarthritis 11/2022 - 11/2019
3	Psoriatic Arthritis 01/2022 - 01/2020
3	Necrosis 09/2020 - 09/2011
3	Ankylosing Spondylitis 01/2020 - 02/2008
2	Arthritis (Polyarthritis) 11/2022 - 10/2009
2	Tuberculosis (Tuberculoses) 01/2020 - 11/2012
2	Latent Tuberculosis 01/2020 - 11/2012
2	Inflammation (Inflammations) 04/2016 - 01/2015
2	Fatigue 05/2015 - 06/2011
2	Atherosclerosis 11/2013 - 01/2006
2	Infections 11/2012 - 02/2008
2	Pain (Aches) 06/2011 - 01/2009
1	Spondylarthritis (Spinal Arthritis) 11/2022
1	Non-Radiographic Axial Spondyloarthritis 09/2020
1	Giant Cell Arteritis (Horton Disease) 04/2016
1	Systemic Scleroderma (Systemic Sclerosis) 01/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2013
1	Rheumatic Diseases (Rheumatism) 03/2012
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2012
1	Autoimmune Diseases (Autoimmune Disease) 01/2012
1	Mental Fatigue 06/2011
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2009
1	Drug-Related Side Effects and Adverse Reactions 10/2009
1	Osteitis 02/2008

Drug/Important Bio-Agent (IBA)

5	Antirheumatic Agents (DMARD)IBA 11/2022 - 09/2008
5	Pharmaceutical PreparationsIBA 11/2022 - 11/2019
5	Biological ProductsIBA 01/2020 - 04/2011
5	Rituximab (Mabthera)FDA Link 01/2017 - 09/2011
4	Tumor Necrosis Factor InhibitorsIBA 11/2022 - 09/2011
3	Serum Amyloid A Protein (Serum Amyloid A)IBA 04/2016 - 11/2013
3	Leflunomide (Arava)FDA LinkGeneric 03/2012 - 09/2008
2	secukinumabIBA 01/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 04/2016 - 01/2015
2	Prostaglandins AIBA 05/2015 - 06/2011
2	AutoantibodiesIBA 01/2012 - 09/2011
2	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 10/2009 - 09/2008
1	C-Reactive ProteinIBA 01/2022
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	HaptoglobinsIBA 04/2016
1	GlucocorticoidsIBA 04/2016
1	Fibrinogen (Factor I)FDA Link 04/2016
1	Prednisolone (Predate)FDA LinkGeneric 04/2016
1	N-phthaloylglutamic acidIBA 05/2015
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2015
1	Methotrexate (Mexate)FDA LinkGeneric 03/2012
1	AntibodiesIBA 01/2012
1	Cytochrome P-450 CYP2C19IBA 10/2009
1	dopastinIBA 10/2009
1	teriflunomideIBA 10/2009
1	Oxygen (Dioxygen)IBA 01/2009
1	NitrogenIBA 01/2009
1	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2006

Therapy/Procedure

4	Therapeutics 11/2022 - 02/2008
2	Chemoprevention 01/2020 - 11/2012
1	Retreatment 01/2017
1	Foot Orthoses 01/2009